4//SEC Filing
Bodenstedt Matthias 4
Accession 0001213900-23-097671
CIK 0001821586other
Filed
Dec 20, 7:00 PM ET
Accepted
Dec 21, 4:01 PM ET
Size
7.3 KB
Accession
0001213900-23-097671
Insider Transaction Report
Form 4
Bodenstedt Matthias
Chief Financial Officer
Transactions
- Sale
Class A ordinary shares, par value $0.0001 per share
2023-12-19$59.22/sh−94,736$5,610,266→ 526,167 total - Sale
Class A ordinary shares, par value $0.0001 per share
2023-12-20$58.34/sh−5,264$307,102→ 520,903 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2023.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.655 to $60.13. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $57.53 to $59.27. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Documents
Issuer
MoonLake Immunotherapeutics
CIK 0001821586
Entity typeother
Related Parties
1- filerCIK 0001920545
Filing Metadata
- Form type
- 4
- Filed
- Dec 20, 7:00 PM ET
- Accepted
- Dec 21, 4:01 PM ET
- Size
- 7.3 KB